News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't live for the approval of others. Only person who can approve what you do is YOU.
Yeah , sure but that being said it doesn't figure that you would not research the management of this Team and family member Avtar Dillion who just plead guilty to the SEC x 3 counts .
especially with your impressive Resume' .....
You got something to say to someone why don't you say something meaningful don't breathe?
Out here I'm trying to make some risk liquidity and some investment and avoid dilution should that be done as any part of investing son?
There are currently no less than 5 prescription medications available for IOP disorder , the most commonly prescribed would be Xalatan . if Skye got SBI-100 all the way through FDA approval , Why would this product be superior ?
and ....thus prescribed more so than the widely known Xalatan ?
what kind of market share $$$ are we talking to re-invent the wheel ?
TIA.....
That I in paid for it to gain with the company and value to my position how does it not make sense son what's the demand here what are you trying to alliterate?
|
Followers
|
140
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6310
|
|
Created
|
11/12/14
|
Type
|
Free
|
| Moderators | |||
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public
